Literature DB >> 10510148

A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening.

P Danjou1, I Paty, R Fruncillo, P Worthington, M Unruh, W Cevallos, P Martin.   

Abstract

AIMS: To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening.
METHODS: Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double-blind to 36 healthy subjects under standardized conditions in a six-period, incomplete-block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered.
RESULTS: No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night.
CONCLUSIONS: The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510148      PMCID: PMC2014318          DOI: 10.1046/j.1365-2125.1999.00024.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.

Authors:  C R Rush; R R Griffiths
Journal:  J Clin Psychopharmacol       Date:  1996-04       Impact factor: 3.153

2.  Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics.

Authors:  H Allain; A Patat; A Lieury; F Le Coz; C Janus; G Menard; J Gandon
Journal:  Eur Psychiatry       Date:  1995       Impact factor: 5.361

3.  Prevalence of sleep disturbance in a primarily urban Florida County.

Authors:  I Karacan; J I Thornby; M Anch; C E Holzer; G J Warheit; J J Schwab; R L Williams
Journal:  Soc Sci Med       Date:  1976-05       Impact factor: 4.634

Review 4.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

5.  A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.

Authors:  B Beer; J R Ieni; W H Wu; D Clody; P Amorusi; J Rose; T Mant; J Gaudreault; A Cato; W Stern
Journal:  J Clin Pharmacol       Date:  1994-04       Impact factor: 3.126

Review 6.  Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; H R Ochs; R I Shader
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

Review 7.  Psychomotor function and psychoactive drugs.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

8.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

Authors:  D J Greenblatt; J S Harmatz; L L von Moltke; B L Ehrenberg; L Harrel; K Corbett; M Counihan; J A Graf; M Darwish; P Mertzanis; P T Martin; W H Cevallos; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1998-11       Impact factor: 6.875

Review 9.  Rational basis for the use of sleeping pills.

Authors:  W C Dement
Journal:  Int Pharmacopsychiatry       Date:  1982

10.  Chronic use of benzodiazepines and psychomotor and cognitive test performance.

Authors:  I Lucki; K Rickels; A M Geller
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

View more
  27 in total

Review 1.  Hypnotics: an update.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task.

Authors:  Karina A Zanin; Camilla L Patti; Leandro Sanday; Luciano Fernandes-Santos; Larissa C Oliveira; Dalva Poyares; Sergio Tufik; Roberto Frussa-Filho
Journal:  Psychopharmacology (Berl)       Date:  2012-06-23       Impact factor: 4.530

Review 3.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  The effect of two benzodiazepine receptor agonist hypnotics on sleep-dependent memory consolidation.

Authors:  Janine M Hall-Porter; Paula K Schweitzer; Rhody D Eisenstein; Hasan Ali H Ahmed; James K Walsh
Journal:  J Clin Sleep Med       Date:  2014-01-15       Impact factor: 4.062

5.  Use of non-benzodiazepine sedative hypnotics and risk of falls in older men.

Authors:  Susan J Diem; Susan K Ewing; Katie L Stone; Sonia Ancoli-Israel; Susan Redline; Kristine E Ensrud
Journal:  J Gerontol Geriatr Res       Date:  2014-07-01

Review 6.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 7.  Residual effects of hypnotics: epidemiology and clinical implications.

Authors:  Annemiek Vermeeren
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

Authors:  Thomas Roth; Steven G Hull; D Alan Lankford; Russell Rosenberg; Martin B Scharf
Journal:  Sleep       Date:  2008-09       Impact factor: 5.849

Review 9.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.

Authors:  Julia Boyle; Philippe Danjou; Robert Alexander; Nicole Calder; Cynthia Gargano; Nancy Agrawal; Irong Fu; Jacqueline B McCrea; M Gail Murphy
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.